Talk Risk-Based Quality Management track
The Real Cost of Delays in Drug Development and the Role of RBQM and QbD
Tue, Oct 29, 2024 · 10:40–10:53 AM CET InterContinental Barcelona
About this session
Session: LEVERAGING QTLs AND KRIs FOR CLINICAL RISK DETECTION
Sponsored presentation.
Discover how the recent Tufts CSDD study aligns with the approach Cyntegrity embedded in their Clinical Monitoring Cost Savings Calculator, launched earlier this year. The study challenges the outdated $4 million/day delay cost, validating how integrated RBQM and QbD strategies can save up to $2.8 million per study. These strategies improve trial efficiency and ensure more effective cost management, making them essential tools in today’s clinical research landscape.
Speaker
-
PhD, Chief Scientific Officer · Cyntegrity Germany GmbH
Speaker